Table 1.
Basic Characteristics of Vaccinated Patients With and Without IBD in the Matched Cohort
| Non-IBD (n = 4946) | IBD (n = 4946) | P value | SMD | |
|---|---|---|---|---|
| Age (y) | 51 ± 16 | 51 ± 16 | 1 | <0.001 |
| <18 | 20 (0.4%) | 20 (0.4%) | ||
| 18–39 | 1288 (26%) | 1288 (26%) | ||
| 40–59 | 2047 (41%) | 2047 (41%) | ||
| 60–69 | 823 (17%) | 823 (17%) | ||
| 70–79 | 627 (13%) | 627 (13%) | ||
| 80+ | 141 (3%) | 141 (3%) | ||
| Sex, male | 2412 (49%) | 2412 (49%) | 1 | <0.001 |
| Duration of follow-up after second vaccine (weeks) | 22 (4–24) | 22 (4–24) | 1 | <0.001 |
| IBD type | ||||
| CD | — | 2447 (49%) | — | — |
| UC | — | 2499 (51%) | — | — |
| Disease duration (y) | — | 12 (1–24) | — | — |
| Treatment during the preceding year | ||||
| Mesalamine | — | 1441 (29%) | <.001 | 0.91 |
| Corticosteroid | — | 203 (4%) | <.001 | 0.29 |
| Immunomodulator | — | 294 (6%) | <.001 | 0.36 |
| Anti-TNF | — | 487 (10%) | <.001 | 0.47 |
| Vedolizumab | — | 185 (4%) | <.001 | 0.28 |
| Ustekinumab | — | 96 (2%) | <.001 | 0.2 |
| Tofacitinib | — | 28 (1%) | <.001 | 0.11 |
| IBD hospitalization ever | — | 2329 (47%) | <.001 | 1.33 |
| IBD surgery ever | — | 668 (14%) | <.001 | 0.56 |
| Corticosteroids therapy ever | — | 2722 (55%) | <.001 | 1.57 |
| Preexisting conditions scorea | .011 | 0.073 | ||
| 0 | 2099 (42%) | 2001 (41%) | ||
| 1 | 1388 (28%) | 1352 (27%) | ||
| 2 | 696 (14%) | 736 (15%) | ||
| 3 | 396 (8%) | 404 (8%) | ||
| ≥4 | 367 (7%) | 453 (9%) |
NOTE. Count (%), mean ± standard deviation, or medians (IQR) are presented as appropriate.
CD, Crohn’s disease; IBD, inflammatory bowel diseases; SMD, standardized mean difference; TNF, tumor necrosis factor; UC, ulcerative colitis.
a
Count of total number of preexisting conditions defined by the Centers for Disease Control as risk factors (Appendix 1).